GleamWall
中文EN

EBS Emergent BioSolutions Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1367644 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-17.7%
TTM net income YoY-443.5%
TTM EPS YoY-475.0%
Revenue 3-yr CAGR-16.2%
Net income 3-yr CAGR—

Margins

Gross margin48.4%
Operating margin-27.7%
Net margin-40.2%
FCF margin29.0%
EBITDA margin-18.4%

Returns

ROE-58.2%
ROA-21.2%
ROIC (approx.)-17.3%
Asset turnover0.53x

Leverage & solvency

Liabilities / assets68.5%
Debt / equity1.62x
Current ratio4.58x
Interest coverage-3.96x

Cash quality & payout

Operating cash flow / net income-0.77x
Accruals ratio-37.5%
Payout ratio—
Capex / revenue1.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$110.00M$234.30M$156.10M$148.70M$231.10M$140.90M$222.20M$194.70M
Cost of revenue$80.80M$97.10M$72.00M$84.90M$85.90M$66.90M$88.50M$118.00M
Gross profit$29.20M$137.20M$84.10M$63.80M$145.20M$74.00M$133.70M$76.70M
R&D expense$9.40M$9.20M$10.50M$12.10M$13.50M$12.50M$15.10M$9.10M
SG&A expense$46.50M$44.60M$46.60M$51.10M$38.90M$43.70M$52.40M$60.80M
Operating income-$37.30M-$125.10M$10.50M-$27.90M$76.50M$1.60M$49.90M-$9.50M
Interest expense$9.70M$10.00M$11.00M$14.70M$15.20M$14.70M$14.70M$14.80M
Pretax income-$36.40M-$166.30M$13.40M-$50.70M$57.60M-$16.80M$92.70M-$27.60M
Income tax-$3.70M$13.90M$6.60M$3.90M$6.40M-$4.80M$24.70M$3.70M
Net income-$32.70M-$180.20M$6.80M-$54.60M$51.20M-$12.00M$68.00M-$31.30M
EBITDA-$30.90M-$118.30M$34.00M-$4.40M$83.60M$8.90M$75.30M$16.50M
EPS (basic)-0.64-3.490.13—0.96-0.221.25—
EPS (diluted)-0.64-3.490.07—0.91-0.221.19—
Weighted avg. shares (diluted)51.30M51.60M56.50M—56.50M54.20M57.30M—
Balance sheet
Cash & equivalents$175.70M$139.70M$160.30M$205.40M$245.50M$267.30M$149.10M$105.60M
Receivables$77.50M$190.00M$121.60M$84.20M$149.50M$79.80M$203.70M$154.50M
Inventory$280.90M$303.60M$327.60M$343.40M$356.30M$338.60M$314.00M$311.70M
Current assets$558.20M$666.00M$637.60M$662.50M$786.90M$719.50M$706.80M$598.70M
PP&E, net$174.80M$178.00M$199.40M$205.40M$209.80M$216.10M$221.00M$270.60M
Goodwill———$0———$0
Intangibles$252.50M$261.80M$470.40M$436.50M$452.70M$469.00M$485.20M$501.50M
Total assets$995.20M$1.12B$1.32B$1.32B$1.46B$1.42B$1.43B$1.39B
Current liabilities$122.00M$122.80M$148.70M$132.20M$136.50M$127.10M$111.90M$162.40M
Short-term debt———————$0
Long-term debt$507.70M$581.80M$573.60M$572.10M$663.10M$667.80M$665.70M$663.70M
Total debt$507.70M$581.80M$573.60M$572.10M$663.10M$667.80M$665.70M$663.70M
Total liabilities$682.00M$775.40M$797.30M$796.00M$878.50M$880.90M$873.40M$906.90M
Shareholders' equity$313.20M$341.40M$523.10M$522.60M$582.50M$536.20M$552.70M$482.80M
Net debt$332.00M$442.10M$413.30M$366.70M$417.60M$400.50M$516.60M$558.10M
Shares outstanding51.30M51.30M51.80M52.10M52.70M53.70M54.50M54.30M
Cash flow statement
Operating cash flow$100.10M$56.10M-$33.80M$77.70M-$2.30M$106.40M-$11.20M-$79.90M
Capital expenditure$3.30M$2.10M$2.40M$3.90M$3.40M$2.90M$3.60M$1.70M
Free cash flow$96.80M$54.00M-$36.20M$73.80M-$5.70M$103.50M-$14.80M-$81.60M
Investing cash flow$4.60M-$52.30M-$2.40M-$3.90M-$3.40M$17.20M$59.50M$28.60M
Financing cash flow-$68.70M-$24.40M-$11.40M-$113.90M-$15.90M-$6.40M-$400,000$500,000
Depreciation & amortization$6.40M$6.80M$23.50M$23.50M$7.10M$7.30M$25.40M$26.00M
Stock-based compensation$4.20M$6.90M$1.90M$5.30M$4.80M$4.60M$1.50M$4.30M
Share buybacks$100,000$9.00M$9.00M$9.10M$8.90M$6.90M$0$0

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.